Fraxetin Suppresses Proliferation of Non-Small-Cell Lung Cancer Cells via Preventing Activation of Signal Transducer and Activator of Transcription 3.

In conclusion, these findings suggest that FXT could be a promising lead compound to be used as a novel STAT3 inhibitor and potential antitumor agent for the treatment of NSCLC.
PMID: 31080186 [PubMed - in process]

Source: The Tohoku Journal of Experimental Medicine - May 14, 2019 Category: Research Authors: Zhang Y, Wang L, Deng Y, Zhao P, Deng W, Zhang J, Luo J, Li R Tags: Tohoku J Exp Med Source Type: research